Thus, the researchers found that a decreased kynurenine/tryptophan ratio, which suggests downregulated IDO levels, and their subsequent observation of lower levels of IDO, including IDO-1, links the marker to possible detection of reduced disease progression in pancreatic cancer patients (94). This evidence concerns the gene IDO1 and familial pancreatic carcinoma.